Clinical breast cancer最新文献

{"title":"Breast Cancer in Working-Age Men: A Population-Based Investigation of Global, Regional, and National Disease Burdens Between 1990 and 2021","authors":"Shujin Li ,&nbsp;Jiancheng Mou ,&nbsp;Guoxin Huang ,&nbsp;Xin Zeng ,&nbsp;Yuxiao Mu ,&nbsp;Weimin Hong ,&nbsp;Xuli Meng ,&nbsp;Qinghui Zheng ,&nbsp;Da Qian","doi":"10.1016/j.clbc.2025.07.014","DOIUrl":"10.1016/j.clbc.2025.07.014","url":null,"abstract":"<div><h3>Background</h3><div>The breast cancer (BC) disease burden in working-age men was investigated between 1990 and 2021.</div></div><div><h3>Methods</h3><div>Age-standardized incidence rates (ASIRs), prevalence rates ASPRs), and death rates (ASDRs), as well as age-standardized disability-adjusted life years rate (DALYs) on global, regional, and national levels between 1990 and 2021, were determined to assess the BC disease burden in working-age men (aged 15-64 years), together with risk factor and health inequality analyses.</div></div><div><h3>Results</h3><div>Globally, the ASIR, ASPR, ASDR, and age-standardized DALY rate in 2021 were 0.77 per 100,000 males (0.46‒0.99), 6.34 per 100,000 males (3.97‒8.02), 0.22 per 100,000 males (0.14‒0.28), and 8.75 per 100,000 males (5.58‒11.40), respectively. The burden of disease varied among regions and countries. Risk factor analysis revealed a marked influence of diets high in red meat on the ASDR and age-standardized DALY rate. Cross-national social inequality analysis identified marked inequalities, both relative and absolute, in the disease burden among regions, with higher burdens found in countries with lower sociodemographic indices.</div></div><div><h3>Conclusions</h3><div>The BC disease burden has escalated in men of working age, accompanied by a decline in life expectancy since the 1990s and increases in associated deaths and DALYs. Low-income regions exhibited a more substantial burden compared to high-income regions. The key to reducing the disease burden lies in enhancing national economic strength, with improvements in medical systems and the development of targeted clinical guidelines.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 7","pages":"Pages 680-692"},"PeriodicalIF":2.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Resistance Training at Different Intensities on Preventing Breast Cancer-Related Lymphedema: A 1-Year Randomized Controlled Trial.","authors":"Yi-Jing Fan, Hui-Qian Xu, Hong Li, Zi-Rui Zhang, Shu-Fang Zhang, Ai-Jun Du, Li-Zhi Zhou, Yang Wang","doi":"10.1016/j.clbc.2025.07.012","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.07.012","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer-related lymphedema (BCRL) is a relatively common and harmful complication after breast cancer surgery, and there is currently no effective cure. We hypothesized that, compared with the control group, 12 weeks of resistance exercise at different intensities could reduce the incidence of BCRL after axillary lymph node dissection.</p><p><strong>Methods: </strong>114 breast cancer patients undergoing axillary lymph node dissection were randomly divided into a Control Group (CG), a Low-to-Moderate Intensity Exercise Group (L-MIEG, 40%-70% 1-RM) and a Moderate-to-High Intensity Exercise Group (M-HIEG, 60%-85% 1-RM).</p><p><strong>Results: </strong>(1) The 12-month cumulative BCRL incidence was higher in the CG (16.3%, 6/37) than in the L-MIEG (8.3%, 3/36) and M-HIEG (5.5%, 2/37). (2) Postintervention and at 6-and 12- month follow-ups, both intervention groups had smaller interlimb differences than the CG (P < .05), and the M-HIEG had smaller differences at 6-month than the L-MIEG (P < .05). (3) InBody analysis showed both intervention groups outperformed CG in segmental water differences, extracellular water (ECW), and single-frequency bioelectrical impedance analysis (SFBIA) (P < .05), and the M-HIEG was better at 6-month (P < .05). (4) At 6-and 12-month follow-ups, both intervention groups improved grip strength more than CG (P < .05), and the M-HIEG was superior at 12 months (P < .05).</p><p><strong>Conclusions: </strong>Different- intensity resistance exercises benefit BCRL prevention, with M-HIEG being more effective.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study on Different Staining Platforms for HER2 Cytoplasmic Granular Staining Pattern in Pure Apocrine Carcinoma of the Breast.","authors":"Xue-Xue Xiao, Peng-Fei Xu, Ming-Wei Wang, Su Jin, Na Fang, Jun-Qiu Yue","doi":"10.1016/j.clbc.2025.07.016","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.07.016","url":null,"abstract":"<p><strong>Objective: </strong>Accurate interpretation of HER2 low/ultralow expression has attracted increasing attention. This study aimed to explore the characteristics and interpretation strategies for the HER2 cytoplasmic granular staining pattern observed in pure apocrine carcinoma (AC), while investigating its impact on the interpretation of HER2 low/ultra-low expression cases.</p><p><strong>Methods: </strong>The clinicopathologic information of 74 patients with pure AC and their previous HER2 (PATHWAY 4B5, Ventana platform) IHC results were retrospectively collected. All enrolled cases underwent Dako HER2 (HercepTest [poly]) IHC staining, among which 43 cases were further subjected to FISH testing. Clinical targeted drug information was collected concurrently.</p><p><strong>Results: </strong>Previous PATHWAY 4B5 staining revealed punctate and/or diffuse cytoplasmic granular staining in 35.14% (26/74) of pure AC. In contrast, only 9 cases (12.16%, 9/74) of HercepTest staining exhibited cytoplasmic granular staining, all of which belonged to the PATHWAY 4B5 cytoplasmic granular staining subset (34.62%, 9/26). HercepTest IHC interpretation demonstrated 89.19% (66/74) concordance with PATHWAY 4B5 interpretations. Furthermore, 88.46% (23/26) of PATHWAY 4B5 cytoplasmic granular staining cases exhibited concordant interpretations between both antibody platforms. 44.59% (33/74) were HER2-positive, and 55.41% (41/74) were triple-negative apocrine carcinoma (TNAC). About 18.19% (6/33) of HER2-positive cases and 48.78% (20/41) of TNAC cases showed cytoplasmic granular staining on PATHWAY 4B5, and 95.00% (19/20) of the latter cases were HER2 low expression.</p><p><strong>Conclusions: </strong>Pure ACs on the PATHWAY 4B5 platform primarily present HER2 cytoplasmic granular staining in TNAC and HER2 low expression cases. The rate of HER2 cytoplasmic granular staining on HercepTest platform was significantly lower than that of PATHWAY 4B5, and is more suitable for the detection and interpretation of HER2 0 and low expression cases.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CDK4/6 Inhibition Beyond Progression in Post-MONARCH: Are We Seeing the Full Picture?","authors":"David Garcia-Martinez,&nbsp;Iván Oterino-Moreira,&nbsp;Susana Lorenzo-Giménez,&nbsp;María Segura-Bedmar","doi":"10.1016/j.clbc.2025.07.007","DOIUrl":"10.1016/j.clbc.2025.07.007","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 7","pages":"Pages 613-616"},"PeriodicalIF":2.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Residual Axillary Lymph Node Metastases After Neoadjuvant Treatment in Breast Cancer.","authors":"Rodrigo Vaz Reis, Paula Pinto, Bárbara Peleteiro, José Luís Fougo","doi":"10.1016/j.clbc.2025.07.011","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.07.011","url":null,"abstract":"<p><strong>Background: </strong>The present study aims to evaluate the volume of residual axillary nodal disease after neoadjuvant chemotherapy (NACT) in breast cancer.</p><p><strong>Methods: </strong>Predictive factors for low-volume residual axillary nodal disease were analyzed in patients with histologically proven breast cancer (cT1-3 cN0-2) who were treated with NACT and surgery between 2015 and 2019.</p><p><strong>Results: </strong>A total of 734 patients were analyzed. Breast pathological complete response (pCR) was achieved in 35.1%, with 31.5% showing no residual tumor in the breast or axillary lymph nodes (LNs). Breast and axillary pCR rates varied according to receptor subtype, with the highest rates found in HER2+ and hormone receptor (HR) negative tumors. Among 385 patients presenting with axillary metastases at diagnosis, 41.0% achieved axillary pCR, and 38.4% had 1-3 metastatic LNs. Predictive factors for axillary pCR included cN stage, HR status, ycN status, and breast pCR. For breast pCR patients with cN+ at presentation, the rate of axillary pCR was 81.1%. After NACT, 68.7% of patients with >2 metastatic LNs at diagnosis had 0-3 residual LNs.</p><p><strong>Conclusion: </strong>We conclude that breast pCR, HER2+, HR negative breast cancer, <3 metastatic axillary LNs at diagnosis, and complete axillary imaging response after NACT were associated with axillary pCR rates and low probability of >3 positive LNs. Similarly, our study showed that axillary pCR in patients with more than 2 metastatic LNs was comparable to that of patients with 1-2 metastatic LNs highlighting an opportunity to tailor axillary surgery in this subgroup.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144788394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Imaging Biomarkers to Improve Equity in Supplemental and High-Risk Breast Cancer Screening Between Black and White Women: A Perspective on Background Parenchymal Enhancement and Breast Density.","authors":"Mattia A Mahmoud, Oluwadamilola M Fayanju, Anne Marie McCarthy, Carla R Zeballos Torrez, Christine E Edmonds","doi":"10.1016/j.clbc.2025.07.009","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.07.009","url":null,"abstract":"<p><strong>Purpose: </strong>Breast density is recognized as a well-established risk factor for breast cancer, influencing screening recommendations. While quantitative measures of breast density have been developed to address limitations of qualitative measures, the role of racial differences in quantitative measures and their effect on breast cancer risk, especially in Black women, remains unclear. Additionally, while background parenchymal enhancement (BPE) is an established as a predictor of breast cancer risk, no research has been conducted to investigate whether the impact of BPE varies by race or ethnicity. This perspective reviews existing data on BPE, specifically its relationship with breast density and breast cancer risk and emphasizes the need for further investigation in Black women.</p><p><strong>Discussion: </strong>Current supplemental screening methods are heavily reliant on qualitative breast density assessments, which may disadvantage Black women. Although BPE has been significantly associated with breast cancer risk independent of breast density, no studies were found that explored the relationship between BPE and breast cancer risk in Black women.</p><p><strong>Conclusion: </strong>The limited data on absolute quantitative density measures, such as dense volume, which could improve screening practices, is highlighted in this review. While BPE is well-established as a breast cancer risk factor, further research is needed to investigate racial differences in BPE and its association with breast cancer risk, particularly among Black women.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Treatment Patterns and Outcomes in Hormone Receptor Positive HER2 Negative Early-Stage Breast Cancer in a Private Community Oncology Practice of Brazil","authors":"Aline Coelho Gonçalves MD ,&nbsp;Tomas Reinert ,&nbsp;Heloisa Mussato Fernandes da Cruz ,&nbsp;Matheus Costa e Silva ,&nbsp;Max S. Mano ,&nbsp;Cristiano Augusto Andrade de Resende ,&nbsp;Gustavo Bretas ,&nbsp;Leandro Jonata de Carvalho Oliveira ,&nbsp;Maria Cristina Figueroa ,&nbsp;Rafael Duarte Paes ,&nbsp;Jorge Alexandre Canedo ,&nbsp;Fernanda Christtanini Koyama ,&nbsp;Carolina Tosin Bueno ,&nbsp;Érica Câmara Mattos de Capps Ferreira ,&nbsp;Carlos Barrios ,&nbsp;Rodrigo Dienstmann","doi":"10.1016/j.clbc.2025.07.010","DOIUrl":"10.1016/j.clbc.2025.07.010","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aims to assess the disease characteristics, practice patterns and real-world outcomes of patients (pts) with HR positive (+)/HER2 negative (-) early breast cancer (EBC) treated in Brazil's largest network of community oncology practices.</div></div><div><h3>Methods</h3><div>Retrospective study from the Oncoclínicas&amp;CO real-world database from 2016 to 2021. We assessed risk profile distribution (high-risk [HR], intermediate-risk [IR] or low-risk [LR]) as per recent adjuvant trials in EBC, endocrine and chemotherapy (CT) prescriptions and 3-year invasive disease-free survival (iDFS).</div></div><div><h3>Results</h3><div>In total, 1,786 cases were selected for the study. Median age was 57 years, 566 (32%) were premenopausal, 1,179 (66%) were LR, 351 (20%) IR, and 256 (14%) HR. In postmenopausal pts, aromatase inhibitor (AI) was used by 74% with LR, 79% with IR and 83% with HR. In premenopausal pts, ovarian function suppression (OFS) – combined with tamoxifen or AI – was prescribed to 18% LR pts, 15% IR, and 48% HR. CT was offered to 32%, 38%, and 73% of postmenopausal pts in LR, IR, and HR groups. In premenopausal pts, 55%, 57%, and 78% received CT in LR, IR, and HR groups. The 3-year iDFS was 86% (95% CI, 84%-89%) in LR population, 87% (82%-91%) in IR, and 72% (95% CI, 65%-81%) in HR.</div></div><div><h3>Conclusions</h3><div>In this large real-world cohort of patients treated in a private setting in Brazil, most pts are diagnosed with low-risk EBC. We found that a significant proportion of premenopausal pts with high-risk EBC were not treated with OFS and did not receive CT.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 7","pages":"Pages 672-679"},"PeriodicalIF":2.5,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention's Price-30-Day Outcomes of Risk-Reducing Mastectomy and Immediate Free Flap Breast Reconstruction.","authors":"Samuel Knoedler, Fortunay Diatta, Kevin Hu, Felix Klimitz, Julius M Wirtz, Thomas Schaschinger, Filippo A G Perozzo, Giuseppe Sofo, Francesco Marena, Bong-Sung Kim, Bohdan Pomahac, Martin Kauke-Navarro","doi":"10.1016/j.clbc.2025.07.003","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.07.003","url":null,"abstract":"<p><strong>Background: </strong>Risk-reducing mastectomy (RRM) with free flap breast reconstruction (FFBR) is increasingly utilized for breast cancer prevention. While its oncological benefits are well-established, data on perioperative safety remain limited. To address this gap, we analyzed postoperative outcomes and risk factors for complications utilizing the American college of surgeons national surgical quality improvement program (ACS-NSQIP) database.</p><p><strong>Methods: </strong>The American college of surgeons national surgical quality improvement program (ACS-NSQIP) (2008-2022) database was queried to identify adult female patients who underwent RRM-FFBR. Primary outcomes included 30-day rates of reoperation, readmission, and surgical or medical complications. Confounder-adjusted multivariate logistic regression was used to identify factors associated with postoperative complications.</p><p><strong>Results: </strong>A total of 985 patients were included, with a mean age and BMI of 46 ± 9.4 years and 31 ± 5.7 kg/m², respectively. The most common comorbidities were obesity (n = 492; 50%) and hypertension (n = 170; 17%). Complications occurred in 171 (17%) cases, with 134 (14%) reoperations and 69 (7.0%) readmissions. 125 (13%) surgical complications were recorded, the majority of which were bleeding events (n = 105; 11%). Medical complications were rare (n = 33; 3.4%). Multivariable analyses revealed that higher hypertension (OR 1.8; 95% CI, 1.1-2.8; P = .017) and diabetes (OR 2.2.; 95% CI, 1.1-4.6; P = .031) were significantly associated with the occurrence of postoperative complications.</p><p><strong>Conclusion: </strong>This multi-institutional study revealed 30-day complication and reoperation rates of 17% and 14%, respectively, following RRM-FFBR. Hypertension and diabetes were significant predictors of postoperative morbidity. Preoperative optimization of these modifiable risk factors may help improve surgical outcomes. These findings underscore the importance of individualized patient management and informed decision-making in RRM-FFBR.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Farnesyltransferase Inhibitor (R115777) Targets CENPF to Inhibit Breast Cancer Bone Metastasis by Regulating the PI3k/AKT/mTOR/PTHrP Pathway.","authors":"Jialong Liu, Jingbo Sun, Hongquan Fang, Junjie Luo, Mee Phangphongphanh, Yang Zou, Yiyi Jin, Xinyi Tao, Kun Zhou, Yunyao Deng, Lixin Liu, Gang Xiao, Ninglei Li, Xiaolong Liu","doi":"10.1016/j.clbc.2025.07.002","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.07.002","url":null,"abstract":"<p><strong>Background: </strong>Farnesyltransferase inhibitor R115777 has shown promising antitumor effects in various types of cancer by targeting RAS proteins and CENPF farnesylation. To explore its potential in breast cancer (BC), In our study, we aimed to uncover its specific efficacy and underlying mechanisms.</p><p><strong>Methods: </strong>Through knockdown experiments, we observed that inhibiting CENPF effectively suppressed the growth and metastasis of BC cells, both in vitro and in vivo.</p><p><strong>Results: </strong>Remarkably, R115777 displayed a selective affinity for CENPF, leading to the inhibition of its-mediated proliferation and bone metastasis in BC cells. Further investigation unveiled that this inhibitory effect was linked to the activation of the PI3K-AKT-mTOR signaling pathway by R115777. Consequently, the secretion of parathyroid hormone-related peptide (PTHrP), a factor crucial for bone marrow development, was detected and inhibited by R115777. As a result, this cascade of events significantly impeded bone metastasis in BC.</p><p><strong>Conclusion: </strong>Our findings highlight the potential of R115777 as a novel therapeutic strategy for preventing bone metastasis in breast cancer. By specifically targeting CENPF and modulating the PI3K-AKT-mTORC1 pathway, R115777 emerges as a promising targeted treatment option in combating the progression and metastasis of breast cancer.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examining the Interrelationships of Lymphedema with Pain, Physical Function, and Demographic and Medical Variables in Women with Breast Cancer and Pain.","authors":"Grace H Amaden, Kelly A Hyland, Joseph G Winger, Sarah A Kelleher, Allison K Diachina, Shannon N Miller, Kelly Westbrook, Gretchen Kimmick, Linda Sutton, Mei R Fu, Tamara J Somers","doi":"10.1016/j.clbc.2025.07.008","DOIUrl":"10.1016/j.clbc.2025.07.008","url":null,"abstract":"<p><strong>Purpose: </strong>To examine the relationship of lymphedema with pain, physical function, and demographic and medical variables in women with breast cancer and pain.</p><p><strong>Methods: </strong>Secondary analysis of baseline data from a study of women with breast cancer and pain. Self-report questionnaires assessed lymphedema, pain severity, pain medication use behavior, pain-related cognitions (ie, pain self-efficacy, pain catastrophizing), and physical function (ie, basic and intermediate activities of daily living (ADLs)). Demographic and medical variables were extracted from the medical record. Univariate analyses examined relationships among lymphedema and variables of interest.</p><p><strong>Results: </strong>Women (N = 347, M_age = 57 years, 63% White) reported moderate pain severity (M = 4.04). Twenty-six percent of women (n = 85) reported having lymphedema. Women with lymphedema endorsed greater pain severity (P = .007) and pain catastrophizing (P = .015) than women without lymphedema; groups did not differ on pain medication use or pain self-efficacy. Women with lymphedema reported a reduced capacity to complete intermediate ADLs compared to women without lymphedema (P = .044); groups did not differ on ability to complete basic ADLs. Women with lymphedema were more likely to be non-White, have lower educational attainment, have undergone lymph node removal or dissection, and received radiation therapy.</p><p><strong>Conclusion: </strong>In women with breast cancer and moderate pain, lymphedema is associated with greater pain severity and pain catastrophizing, and decreased ability to complete intermediate ADLs. Women with lymphedema and pain may benefit from tailored, accessible cognitive-behavioral-physiological interventions to improve self-management (eg, Pain Coping Skills Training, interventions to promote lymph flow and reduce inflammation). Disparities in lymphedema prevalence by race and education warrant further exploration.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}